Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 4/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.31 |
| ▸ | BRS3 | P32247 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723660 | 0.79 | GRM5 (0.43) | IDH1GRM5HTR2AASIC3NOS3 | |
| SCHEMBL10130883 | 0.73 | IDH1 (0.43) | IDH1ASIC3NOS3NOS1LARS1 | |
| SCHEMBL10130898 | 0.72 | GRM5 (0.48) | IDH1GRM5HTR2ANOS3NOS1 | |
| SCHEMBL12680213 | 0.71 | ASIC3 (0.42) | IDH1ASIC3NOS3NOS1BRS3 | |
| SCHEMBL13723803 | 0.70 | IDH1 (0.39) | IDH1GRM5ASIC3NOS3NOS1 | |
| SCHEMBL13722749 | 0.70 | IDH1 (0.41) | IDH1GRM5ASIC3NOS3NOS1 | |
| SCHEMBL15633015 | 0.69 | CYP2A6 (0.40) | GRM5CYP1A2CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL12681427 | 0.69 | CCR1 (0.59) | IDH1CYP2A6ASIC3NOS3NOS1 | |
| SCHEMBL10161832 | 0.68 | NPC1 (0.42) | IDH1ASIC3NOS3NOS1BRS3 | |
| SCHEMBL13514037 | 0.66 | SMN1; SMN2 (0.49) | ASIC3NOS3NOS1BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | CYP2C8, CCR8, CXCL8 | IDH1 3129/4885GRM5 4412/4885CYP1A2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.